TY - JOUR
T1 - Rationale and design of the MULTISTARS AMI Trial
T2 - A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease
AU - on behalf of the MULTISTARS AMI Investigators
AU - Stähli, Barbara E.
AU - Varbella, Ferdinando
AU - Schwarz, Bettina
AU - Nordbeck, Peter
AU - Felix, Stephan B.
AU - Lang, Irene M.
AU - Toma, Aurel
AU - Moccetti, Marco
AU - Valina, Christian
AU - Vercellino, Matteo
AU - Rigopoulos, Angelos G.
AU - Rohla, Miklos
AU - Schindler, Matthias
AU - Wischnewsky, Manfred
AU - Linke, Axel
AU - Schulze, P. Christian
AU - Richardt, Gert
AU - Laugwitz, Karl Ludwig
AU - Weidinger, Franz
AU - Rottbauer, Wolfgang
AU - Achenbach, Stephan
AU - Huber, Kurt
AU - Neumann, Franz Josef
AU - Kastrati, Adnan
AU - Ford, Ian
AU - Ruschitzka, Frank
AU - Maier, Willibald
N1 - Publisher Copyright:
© 2020 The Authors
PY - 2020/10
Y1 - 2020/10
N2 - About half of patients with acute ST-segment elevation myocardial infarction (STEMI) present with multivessel coronary artery disease (MVD). Recent evidence supports complete revascularization in these patients. However, optimal timing of non-culprit lesion revascularization in STEMI patients is unknown because dedicated randomized trials on this topic are lacking. Study design: The MULTISTARS AMI trial is a prospective, international, multicenter, randomized, two-arm, open-label study planning to enroll at least 840 patients. It is designed to investigate whether immediate complete revascularization is non-inferior to staged (within 19-45 days) complete revascularization in patients in stable hemodynamic conditions presenting with STEMI and MVD and undergoing primary percutaneous coronary intervention (PCI). After successful primary PCI of the culprit artery, patients are randomized in a 1:1 ratio to immediate or staged complete revascularization. The primary endpoint is a composite of all-cause death, non-fatal myocardial infarction, ischemia-driven revascularization, hospitalization for heart failure, and stroke at 1 year. Conclusions: The MULTISTARS AMI trial tests the hypothesis that immediate complete revascularization is non-inferior to staged complete revascularization in stable patients with STEMI and MVD.
AB - About half of patients with acute ST-segment elevation myocardial infarction (STEMI) present with multivessel coronary artery disease (MVD). Recent evidence supports complete revascularization in these patients. However, optimal timing of non-culprit lesion revascularization in STEMI patients is unknown because dedicated randomized trials on this topic are lacking. Study design: The MULTISTARS AMI trial is a prospective, international, multicenter, randomized, two-arm, open-label study planning to enroll at least 840 patients. It is designed to investigate whether immediate complete revascularization is non-inferior to staged (within 19-45 days) complete revascularization in patients in stable hemodynamic conditions presenting with STEMI and MVD and undergoing primary percutaneous coronary intervention (PCI). After successful primary PCI of the culprit artery, patients are randomized in a 1:1 ratio to immediate or staged complete revascularization. The primary endpoint is a composite of all-cause death, non-fatal myocardial infarction, ischemia-driven revascularization, hospitalization for heart failure, and stroke at 1 year. Conclusions: The MULTISTARS AMI trial tests the hypothesis that immediate complete revascularization is non-inferior to staged complete revascularization in stable patients with STEMI and MVD.
UR - http://www.scopus.com/inward/record.url?scp=85089942609&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2020.07.016
DO - 10.1016/j.ahj.2020.07.016
M3 - Article
C2 - 32871329
AN - SCOPUS:85089942609
SN - 0002-8703
VL - 228
SP - 98
EP - 108
JO - American Heart Journal
JF - American Heart Journal
ER -